Frédéric Rolland

Centre Hospitalier René-Dubos — France

Medicine · Health Sciences

51h-index23.4kcitations250works10.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(81), Head and Neck Cancer Studies(51), Bladder and Urothelial Cancer Treatments(39), Cancer Genomics and Diagnostics(38), Cancer Immunotherapy and Biomarkers(37)

Publications246 total

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12
SSRN Electronic Journal·2026Open Access
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
European Urology·2025
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
ESMO Open·2025Open Access
Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).
Journal of Clinical Oncology·2025
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
Journal of Clinical Oncology·2025· 2 cited
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
ESMO Open·2025· 1 citedOpen Access
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
Annals of Oncology·2024· 25 citedOpen Access
909P Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Annals of Oncology·2024Open Access
854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial
Annals of Oncology·2024· 16 cited
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
Journal of Clinical Oncology·2024· 13 cited
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials
European Urology Oncology·2024· 5 cited
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
European Journal of Cancer·2024· 2 citedOpen Access
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
The Lancet Healthy Longevity·2024· 8 citedOpen Access
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort
European Journal of Cancer·2024· 6 citedOpen Access
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study
European Journal of Cancer·2024· 2 cited
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Journal of Clinical Oncology·2024
GCISAVE: A non-comparative randomized phase II study of combination of gemcitabine cisplatin (GCis) +/- avelumab (A) in 1st line treatment for locally advanced or metastatic urothelial bladder carcinoma (MUBC)—GETUG AFU V07.
Journal of Clinical Oncology·2024· 1 cited
PD-L1 Expression and its Prognostic Value in Metastatic Papillary Renal Cell Carcinoma: Results from a GETUG Multicenter Retrospective Cohort
SSRN Electronic Journal·2024· 1 citedOpen Access
Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
Cancer Urology·2023Open Access
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
The Lancet Oncology·2023· 78 cited
page 1 of 13Next →

Frequent Co-authors

Gwénaëlle Gravis(22), Stéphane Oudard(21), Bernard Escudier(19), Brigitte Laguerre(16), Alain Ravaud(14), Christine Chevreau(12), Lionnel Geoffrois(12), R. Delva(12), Sylvie Négrier(11), Florence Joly(11), Christine Théodore(11), Stéphane Culine(11), Claude Linassier(10), Philippe Beuzeboc(9), Laurence Albigès(8), Karim Fizazi(8), Loı̈c Mourey(8), Sylvie Zanetta(8), I. Krakowski(7), G. Deplanque(7)